Other Events ·
Summit Therapeutics announced updated overall survival (OS) analysis from its Phase III HARMONi trial, showing a…
SMMTSummit Therapeutics Inc.
Summit Therapeutics announced updated overall survival (OS) analysis from its Phase III HARMONi trial, showing a hazard ratio of 0.76 for both the full population and western patient subgroups. The results, which demonstrate a consistent efficacy and safety profile for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients, have been provided to the FDA ahead of the November 14, 2026, PDUFA goal action date. Summit Therapeutics is a biopharmaceutical oncology company focused on drug discovery and development.